Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures

1 Jan 2021

Abstract excerpt

Abstract Background Mutations of the isocitrate dehydrogenase (IDH) gene occur in over 80% of low-grade gliomas and secondary glioblastomas. Despite considerable efforts, endogenous in vitro IDH-mutated glioma models remain scarce. Availability of these models is key for the development of new therapeutic interventions. Methods Cell cultures were established from fresh tumor material and expanded in serum-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34595478
DOI: 10.1093/noajnl/vdab103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell culturesPMID 34595478Read ↗

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell culturesSemantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibSemantic proximity Read ↗

Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

Cellular heterogeneity and therapeutic response profiling of human IDH+ glioma stem cell culturesSemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.